Physician profile
Antonio Ucar
NPI 1851388052
$8,871.08
in general payments reported to CMS, 2019-2025
21 companies · $339 in 2025
The $339 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,698 · 2021: $486 · 2022: $41.22 · 2023: $1,744 · 2024: $2,564 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,223 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,725 · Food and Beverage: $368 · Travel and Lodging: $238 · Education: $92.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,222.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,725.00 |
| Food and Beverage | $367.57 |
| Travel and Lodging | $238.30 |
| Education | $92.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $3,353.94 | 2019 | |
| Eisai INC. | $2,289.44 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $1,725.00 | 2023 | Onivyde |
| Incyte Corporation | $485.72 | 2021 | |
| Angiodynamics, INC. | $223.94 | 2019 | |
| Mirati Therapeutics, INC. | $212.50 | 2024 | Krazati |
| E.R. Squibb & Sons, L.L.C. | $168.06 | 2022-2025 | Opdivo |
| Abbvie INC. | $119.90 | 2019 | |
| Seagen INC. | $92.99 | 2025 | |
| Array Biopharma INC | $52.80 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Takeda Pharmaceuticals U.S.A., INC. | $52.40 | 2024-2025 | Fruzaqla, Alunbrig |
| Daiichi Sankyo INC. | $28.81 | 2025 | Enhertu |
| Jazz Pharmaceuticals INC. | $28.76 | 2025 | |
| Adaptive Biotechnologies Corporation | $18.87 | 2023 | Clonoseq |
| Astellas Pharma US INC | $17.95 | 2025 | Xospata |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Ucar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.